SCHEMBL23640344

SCHEMBL23640344

Ic1c(OCc2ccccc2)ccc2ncccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.50
LTA4H P09960 1/20 0.50
CYP3A4 P08684 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
SLC40A1 Q9NP59 1/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 2/20 0.44
SGMS2 Q8NHU3 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CHEK2 O96017 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ROS1 P08922 1/20 0.40
FLT3 P36888 1/20 0.40
ERBB4 Q15303 1/20 0.40
AURKB Q96GD4 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799479 0.80 LTA4H (0.58) MAPK14LTA4HCYP3A4SMN1; SMN2SLC40A1
SCHEMBL27512292 0.78 NPC1 (0.60) MAPK14SMN1; SMN2MAPTL3MBTL1NPC1
SCHEMBL27656755 0.77 KDM4E (0.46) MAPK14LTA4HCYP3A4SMN1; SMN2SLC40A1
SCHEMBL25368507 0.77 CCR5 (0.43) MAPK14SMN1; SMN2RAB9AALDH1A1
SCHEMBL29440862 0.77 CCR5 (0.43) MAPK14SMN1; SMN2RAB9AALDH1A1
SCHEMBL27592091 0.77 LMNA (0.46) MAPK14LTA4HCYP3A4MAPTKDM4E
SCHEMBL5583730 0.76 LTA4H (0.44) MAPK14LTA4HCYP3A4SMN1; SMN2SLC40A1
SCHEMBL24303045 0.76 CA9 (0.52) MAPK14LTA4HSMN1; SMN2SLC40A1MAPT
SCHEMBL9431635 0.76 PLAU (0.50) MAPK14LTA4HSMN1; SMN2MAPTL3MBTL1
SCHEMBL26720238 0.75 LTA4H (0.47) MAPK14LTA4HCYP3A4SMN1; SMN2SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 US disclosed
EP-3848367-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 MAPK14 476/4885LTA4H 4835/4885CYP3A4 4463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.